Skip to main content

Beam Therapeutics, Inc. News

Cathie Wood Watch: This Firm Programs Cells, Using DNA as Code

Wood's Ark Investment Management bought a series of biotech stocks, as it has done repeatedly in recent sessions.

Stocks Close Mixed, Nasdaq Snaps Losing Streak

Stocks finish mixed Monday with the Nasdaq turning positive to snap a four-day losing streak.

Stock Market Today: Inflation Fears Pound Tech, Omicron Wave Tests Growth Bets; Bond Yields Hit 1.8%

Wall Street looks set to extend last week's declines, with tech stocks leading to the downside, ahead of a key reading of December inflation, Jerome Powell testimony and the start of the fourth quarter earnings season.

Beam Therapeutics Stock Active After $1.35 Billion Pfizer Drug Development Deal

Boston-based Beam Therapeutics has agreed to a potential $1.35 billion drug development deal with pharma giant Pfizer.

Intellia Therapeutics Leads Gene-Editing Stock Rally

Intellia Therapeutics rises and other gene-editing stocks follow suit.

Breaking News

Elon Musk Throws Dogecoin a Lifeline

Elon Musk will soon allow Dogecoin to purchase SpaceX merchandise.

Disney Fans Angry, Excited About New Guardians of the Galaxy Ride

The theme park company has opened Guardians of the Galaxy: Cosmic Rewind and not everyone is happy despite the ride getting wonderful reviews.

Aurora Cannabis Slashing Weed Capacity in Profitability Push

Aurora is slashing its production capacity as it builds a runway toward positive Ebitda a year from now.

Costco Beats Q3 Sales Forecast, Membership Revenues Near $1 Billion

Costco took in $984 million in new membership fee in its fiscal third quarter, helping the bulk retailer top Street forecasts for topline revenues.